Access

News and Views

Nature 448, 33-34 (5 July 2007) | doi:10.1038/448033a; Published online 4 July 2007

Open Innovation Challenges

naturejobs

Molecular medicine: Entry granted

Edouard M. Cantin1 & John J. Rossi1

Top

The inability to efficiently deliver small interfering RNAs to target organs hinders their therapeutic application. So a demonstration of siRNA delivery to a notoriously difficult organ — the brain — is very exciting indeed.

The process of RNA interference (RNAi) uses small RNA triggers to decrease gene expression in a sequence-specific manner. In most applications, a small interfering RNA (siRNA) sequence — 21–23 nucleotides long — silences a target messenger RNA with a complementary sequence by either directing site-specific cleavage or inhibiting its translation into a protein1, 2.

  1. Edouard M. Cantin and John J. Rossi are at the Beckman Research Institute of the City of Hope, and City of Hope Graduate School of Biological Sciences, Duarte, California 91010, USA.
    Email: jrossi@bricoh.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

News and Views

Clinical Pharmacology & Therapeutics News and Views